ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 NPSLE
文献概要
神経精神症状を伴う全身性エリテマトーデス（NPSLE）の精神障害として，急性錯乱状態，認知機能障害，精神病性障害，気分障害，不安障害が挙げられている。これらのうち，気分障害（うつ病）と軽度の認知機能障害が最も高頻度に合併する。精神症状の出現と，SLEの生物学的側面の関係性はいまだ明らかになっていない。精神症状のマネジメントとしては，SLEに対する免疫抑制療法が基本であるが，対症的に向精神薬治療や精神療法的アプローチも用いられる。
参考文献
1)ACR ad hoc committee on neuropsychiatric lupus nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999
2)Bertsias GK, Boumpas DT: Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestation. Nat Rev Rheumatol 6: 358-367, 2010
3)Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, et al: The diagnosis and clinical management of the neuropsychiatric manifestation of lupus. J Autoimmun 74: 41-72, 2016
4)Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, et al: Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 69: 529-535, 2010
5)西村勝治, 佐藤恵里: 全身性エリテマトーデス（SLE）における精神障害. 総病精医23: 42-51, 2011
6)日本精神神経学会（日本語版用語監修）, 髙橋三郎, 大野 裕（監訳）: DSM-5精神疾患の診断・統計マニュアル. 医学書院, 東京. 2014
7)Katsumata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, et al: Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 34: 2010-2017, 2007
8)Ad Hoc Committee on Lupus Response Criteria: Cognition Sub-committee, Mikdashi JA, Esdaile JM, Alarcón GS, Crofford L, et al: Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 16: 418-425, 2007
9)Kozora E, Filley CM: Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus. J Int Neuropsychol Soc 17: 385-392, 2011
10)Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, et al: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69: 2074-2082, 2010
11)Nishimura K, Omori M, Katsumata Y, Sato E, Gono T, et al: Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol 42: 441-448, 2015
12)Filley CM: White matter: organization and functional relevance. Neuropsychol Rev 20: 158-173, 2010
13)Appenzeller S, Li LM, Costallat LT, Cendes F: Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus 16: 963-971, 2007
14)Filley CM, Kozora E, Brown MS, Miller DE, West SG, et al: White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol 22: 38-44, 2009
15)Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, et al: Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum 63: 3048-3057, 2011
16)Pego-Reigosa JM, Isenberg DA: Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 47: 1498-1502, 2008
17)Appenzeller S, Cendes F, Costallat LT: Acute psychosis in systemic lupus erythematosus. Rheumatol Int 28: 237-243, 2008
18)Paholpak P, Rangseekajee P, Foocharoen C: Characteristics, treatments and outcome of psychosis in Thai SLE patients. J Psychosom Res 73: 448-451, 2012
19)Isshi K, Hirohata S: Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 41: 1819-1827, 1998
20)Toubi E, Shoenfeld Y: Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6: 119-125, 2007
21)Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, et al: Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54: 312-324, 2006
22)Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H: Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 28: 1319-1323, 2009
23)Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, et al: Depression and systemic lupus erythematosus: a systematic review. Lupus 22: 409-416, 2013
24)Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al: Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rhumatol 67: 1837-1847, 2015
25)Zhang L, Fu T, Yin R, Zhang Q, Shen B: Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry 17: 70, 2017
26)Nery FG, Borba EF, Viana VS, Hatch JP, Soares JC, et al: Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with antiribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 32: 695-700, 2008
27)Eber T, Chapman J, Shoenfeld Y: Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 14: 571-575, 2005
28)Giovacchini G, Mosca M, Manca G, Della Porta M, Neri C, et al: Cerebral blood flow in depressed patients with systemic lupus erythematosus. J Rheumatol 37: 1844-1851, 2010
29)Saito T, Tamura M, Chiba Y, Katsuse O, Suda A, et al: Regional cerebral glucose metabolism in systemic lupus erythematosus patients with major depressive disorder. J Neurol Sci 379: 127-130, 2017
30)Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, et al: Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58: 1214-1220, 2002
31)Bachen LA, Chesney MA, Criswell LA: Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 61: 822-829, 2009
32)Tay SH, Cheung PP, Mak A: Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic erythematosus. Lupus 24: 1392-1399, 2015
33)Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara L, Fraga-Mouret A, et al: Controlled clinical trial of Ⅳ cyclophosphamide versus Ⅳ methylpredonisolone in severe neurological manifestation in systemic lupus erythematosus. Ann Rheum Dis 64: 620-625, 2005
34)Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, et al: Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 65: 1325-1327, 2005
35)Haupt M, Millen S, Jänner M, Falagan D, Fischer-Betz R, et al: Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 64; 1618-1623, 2005
36)Fricchione GL, Kaufman LD, Gruber BL, Fink M: Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia. Am J Med 88: 442-443, 1990
37)深津 亮, 加澤鉄士, 森 秀樹, 山内俊雄: CNSループスにおける向精神薬治療の実際. リウマチ科25: 219-228. 2001
38)Shapiro HS: Psychopathprogy in the patients with lupus. Wallace DJ and Hahn BH (eds): Dubois' Lupus Erythematosus. 5th edition. Williams ＆ Wilkins. Baltimore, 755-782, 1997
39)Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, Coín MA, Robles-Ortega H, et al: Efficasy of cognitive behavioral therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom 79: 107-115, 2010
40)Lewis DA, Smith RE: Steroid-induced psychiatric syndromes. A case report of 14 cases and a review of the literature. J Affect Disord 5: 319-332, 1983
41)Nishimura K, Harigai M, Omori M, Sato E, Hara M: Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology 33: 395-403, 2008
42)Brown ES: Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 1179: 41-55, 2009
43)Tucci P, Morgese MG, Colaianna M, Zotti M, Schiavone S, et al: Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic change. Steroids 77: 269-275, 2012
44)Brown ES, J Woolston DJ, Frol AB, Bobadilla L, Khan DA, et al: Hippocampal volume, spectroscopy, cognition, and mmo in patients receiving corticosteroid therapy. Biol Psychiatry 55: 538-545, 2004
45)Brown ES, Woolston DJ, Frol AB: Amygdala volume in patients receiving chronic corticosteroid therapy. Biol Psychiatry 63: 705-709, 2008
46)Falk WE, Mahnke MW, Poskanzer DC: Lithium prophylaxis of corticotropin-induced psychosis. JAMA 241: 1011-1012, 1979
掲載誌情報
